Optic pathway glioma
Clinical trials for Optic pathway glioma explained in plain language.
Never miss a new study
Get alerted when new Optic pathway glioma trials appear
Sign up with your email to follow new studies for Optic pathway glioma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New proton therapy aims to shield memory in kids with brain cancer
Disease control OngoingThis study tests a new way to give proton radiation to children with low-grade glioma, a common brain tumor. The goal is to avoid the hippocampus, a brain area key for memory, to reduce long-term memory loss. About 74 children will receive this targeted radiation, and researchers…
Matched conditions: OPTIC PATHWAY GLIOMA
Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for kids with NF1 brain tumors: targeted drug may beat chemo
Disease control OngoingThis study compares a targeted drug called selumetinib to standard chemotherapy (carboplatin/vincristine) in children aged 2 to 21 with neurofibromatosis type 1 (NF1) and low-grade glioma, a type of brain tumor. The goal is to see if selumetinib works as well or better at control…
Matched conditions: OPTIC PATHWAY GLIOMA
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a parasite drug fight childhood brain tumors?
Disease control OngoingThis trial is testing whether mebendazole, a drug commonly used to treat intestinal parasites, can help children with brain tumors called gliomas. The study combines mebendazole with standard chemotherapy drugs to see if it is safe and effective. It includes children and young ad…
Matched conditions: OPTIC PATHWAY GLIOMA
Phase 1/2 • Sponsor: Julie Krystal • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Painless eye drops could save sight in kids with brain tumors
Disease control OngoingThis study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…
Matched conditions: OPTIC PATHWAY GLIOMA
Phase 2 • Sponsor: Benedetto Falsini • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC